Sanofi Takes Position in Inozyme Pharma, Inc. (NASDAQ:INZY)

Sanofi acquired a new stake in Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 443,255 shares of the company's stock, valued at approximately $1,228,000. Inozyme Pharma accounts for approximately 0.7% of Sanofi's investment portfolio, making the stock its 8th largest holding. Sanofi owned about 0.69% of Inozyme Pharma at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its position in shares of Inozyme Pharma by 345.5% in the fourth quarter. JPMorgan Chase & Co. now owns 128,872 shares of the company's stock valued at $357,000 after acquiring an additional 99,944 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Inozyme Pharma by 155.7% in the fourth quarter. Renaissance Technologies LLC now owns 421,399 shares of the company's stock valued at $1,167,000 after acquiring an additional 256,599 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Inozyme Pharma by 13.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 504,670 shares of the company's stock valued at $1,398,000 after acquiring an additional 58,518 shares in the last quarter. abrdn plc purchased a new position in shares of Inozyme Pharma in the fourth quarter valued at approximately $472,000. Finally, Barclays PLC lifted its position in shares of Inozyme Pharma by 261.4% in the third quarter. Barclays PLC now owns 76,730 shares of the company's stock valued at $401,000 after acquiring an additional 55,497 shares in the last quarter. 88.30% of the stock is owned by institutional investors and hedge funds.

Inozyme Pharma Trading Up 1.0%

NASDAQ:INZY traded up $0.04 on Monday, reaching $3.99. The company's stock had a trading volume of 8,198,687 shares, compared to its average volume of 773,644. Inozyme Pharma, Inc. has a 12-month low of $0.72 and a 12-month high of $6.24. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. The stock has a 50 day moving average price of $1.15 and a 200 day moving average price of $1.85. The firm has a market cap of $257.60 million, a price-to-earnings ratio of -2.56 and a beta of 1.35.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.01). On average, equities analysts anticipate that Inozyme Pharma, Inc. will post -1.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on INZY. HC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of Inozyme Pharma in a research report on Thursday, April 10th. Raymond James decreased their target price on Inozyme Pharma from $24.00 to $12.00 and set an "outperform" rating on the stock in a research report on Wednesday, March 12th. Wedbush downgraded Inozyme Pharma from a "strong-buy" rating to a "hold" rating in a research report on Friday. Wells Fargo & Company restated an "equal weight" rating and issued a $4.00 target price on shares of Inozyme Pharma in a research report on Friday. Finally, Needham & Company LLC downgraded Inozyme Pharma from a "moderate buy" rating to a "hold" rating in a research report on Friday. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Inozyme Pharma has an average rating of "Moderate Buy" and an average price target of $11.75.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.